iSpecimen Appoints Evan Cox as Vice President of Product Management
June 08 2022 - 7:30AM
iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an
online global marketplace that connects scientists in need of
biospecimens for medical research with a network of healthcare
specimen providers, announced today that the Company has appointed
Evan Cox as Vice President of Product Management, effective
immediately. In this role, Mr. Cox will manage the growth and
future development of the iSpecimen Marketplace™ platform.
“Evan’s previous experience in planning,
developing and delivering technology solutions for leading
healthcare organizations will prove vital as we continue to enhance
and expand our Marketplace offering,” said iSpecimen Founder and
CEO, Christopher Ianelli, MD, Ph.D. “iSpecimen’s mission to equip
all researchers with the invaluable biospecimens needed for their
work comes to life through our technology, and Evan’s guidance and
leadership will ensure that the Marketplace platform continues to
be a true asset to the global medical community.”
Prior to joining iSpecimen, Mr. Cox held several
key senior management roles at Definitive Healthcare Corp., a
provider of healthcare commercial intelligence, most recently as
Associate Vice President, where he led the product management team.
Before that, he held multiple product strategy and decision support
roles at Change Healthcare, a healthcare technology company, where
he focused on artificial intelligence and natural language
processing to streamline existing workflows. In addition, Mr. Cox
co-founded DSE Analytics, a company that used natural language
processing to integrate qualitative and quantitative information
available on Consumer Assessment of Healthcare Providers and
Systems (CAHPS) surveys to deliver providers deep insights into
their satisfaction scores. He also served as Senior Product Manager
of Data Analytics and Research at Press Ganey Associates and
Product Lead of Clinical Data Management at WebMD.
“It is no secret that precision medicine is
driving the demand for more customized biospecimen collections in
today’s medical research,” added Mr. Cox. “Harnessing the power of
iSpecimen’s advanced technology to accelerate medical discovery is
a gamechanger for researchers around the world who are in need of
specimens and data. The key to further optimizing iSpecimen’s
Marketplace platform lies in understanding the new, unique needs of
both researchers searching for biospecimens and healthcare
organizations providing the samples. I look forward to working
alongside management to bring iSpecimen’s technology to the next
level and solidify the Company’s position as a pioneer in the
biospecimen procurement industry.”
About iSpecimeniSpecimen
(Nasdaq: ISPC) offers an online marketplace for human biospecimens,
connecting scientists in commercial and non-profit organizations
with healthcare providers that have access to patients and
specimens needed for medical discovery. Proprietary, cloud-based
technology enables scientists to intuitively search for specimens
and patients across a federated partner network of hospitals, labs,
biobanks, blood centers and other healthcare organizations. For
more information, please visit www.ispecimen.com.
For further information, please contact:
Investor ContactKCSA Strategic
CommunicationsAllison SossiSpecimen@kcsa.com
Media ContactsKCSA Strategic
CommunicationsRaquel Cona / Shana MarinoiSpecimen@kcsa.com
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Aug 2024 to Sep 2024
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Sep 2023 to Sep 2024